Anti-iASPP/PPP1R13L Antilichaam Picoband® 31.0647 Vervoeging

IASPP is one of the most evolutionarily conserved inhibitors of p53 (TP53; MIM 191170), whereas ASPP1 (MIM 606455) and ASPP2 (MIM 602143) are activators of p53.

PPP1R13L; IASPP; NKIP1; PPP1R13BL; RAI; RelA-associated inhibitor; Inhibitor of ASPP protein; Protein iASPP; NFkB-interacting protein 1; PPP1R13B-like protein

PPP1R13L

10848

Q8WUF5

Human, Mouse, Rat

No cross-reactivity with other proteins

E.coli-derived human iASPP/PPP1R13L recombinant protein (Position: D94-Q753) . Human iASPP/PPP1R13L shares 88.8% amino acid (aa) sequence identity with mouse iASPP/PPP1R13L.

Flow Cytometry

Immunogen affinity purified.

Liquid

1. Bergamaschi, D., Samuels, Y., O'Neil, N. J., Trigiante, G., Crook, T., Hsieh, J.-K., O'Connor, D. J., Zhong, S., Campargue, I., Tomlinson, M. L., Kuwabara, P. E., Lu, X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nature Genet. 33: 162-167, 2003. 2. Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., Crook, T., Lu, X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72- polymorphic p53. Nature Genet. 38: 1133-1141, 2006. 3. Falik-Zaccai, T. C., Barsheshet, Y., Mandel, H., Segev, M., Lorber, A., Gelberg, S., Kalfon, L., Ben Haroush, S., Shalata, A., Gelernter-Yaniv, L., Chaim, S., Raviv Shay, D., and 15 others. Sequence variation in PPP1R13L results in a novel form of cardio-cutaneous syndrome. EMBO Molec. Med. 9: 319-336, 2017. Note: Erratum: EMBO Molec. Med. 9: 1326 only, 2017.

At -20 ̊C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

89 kDa

6

Protein phosphatase 1 regulatory subunit 13 like

RelA-associated inhibitor

Rabbit IgG

Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4, 0.02% NaN3.